Lamivudine for the treatment of HIV

Bibliography

• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services; November 3, 2008. Available from: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
   Google Scholar
• Hammer SM, Eron JJ Jr, Reiss P, Antiretroviral treatment of adult HIV infection: 2008 Recommendations of the International AIDS Society–USA Panel. JAMA 2008;300:555-70
   PubMed Web of Science ®Google Scholar
• World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach, 2006 revision. Available from: http://www.who.int/hiv/pub/arv/adult/en/index.html
   Google Scholar
• Soudeyns H, Yao XJ, Gao Q, Anti-human immunodeficiency virus type I activity and in vitro toxicity of 2′-deoxy-3′-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog. Antimicrob Agents Chemother 1991;35:1386-90
   PubMed Web of Science ®Google Scholar
• Skalski V, Chang CN, Dutschman G, The biochemical basis for the differential anti-human immunodeficiency virus activity of two cis enantiomers of 2′,3′-dideoxy-3′-thiacytidine. J Biol Chem 1993;268:23234-8
   PubMed Web of Science ®Google Scholar
• Epivir (lamivudine) prescribing information. GlaxoSmithKline, Research Triangle Park, NC, USA; 2009
   Google Scholar
• Perry CM, Faulds D. Lamivudine: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. Drugs 1997;53:657-80
   PubMed Web of Science ®Google Scholar
• Eron JJ, Benoit SL, Jemsek J, Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200-500 CD4+ cells per cubic millimeter. N Engl J Med 1995;333:1662-9
   PubMed Web of Science ®Google Scholar
• Bartlett JA, Benoit SL, Johnson VA, Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. Ann Intern Med 1996;125:161-72
   PubMed Web of Science ®Google Scholar
• Katlama C, Ingrand D, Loveday C, Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naïve patients: a randomized controlled comparison with zidovudine monotherapy. JAMA 1996;276:118-25
   PubMed Web of Science ®Google Scholar
• Staszewski S, Loveday C, Picazo JJ, Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine- experienced patients: a randomized controlled comparison with zidovudine monotherapy. JAMA 1996;276:111-17
   PubMed Web of Science ®Google Scholar
• Johnson MA, Moore KHP, Yuen GJ, Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet 1999;36:41-66
   PubMed Web of Science ®Google Scholar
• Schurman R, NijhuisM, van Leeuwen R, Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995;171:1411-19
   PubMed Web of Science ®Google Scholar
• Campbell TB, Shulman NS, Johnson SC, Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. CID 2005;41:236-42
   PubMed Web of Science ®Google Scholar
• Castagna A, Danise A, Menzo S, Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-re sistant virus: a randomized pilot study (E-184V study). AIDS 2006;20:795-803
   PubMed Web of Science ®Google Scholar
• Saag MS, Sonnerborg A, Torres RA, Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. Abacavir Phase 2 Clinical Team. AIDS 1998,12:F203-9
   PubMed Web of Science ®Google Scholar
• Louie M, Hogan C, Hurley A, Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1 infected individuals. AIDS 2003;17:1151-6
   PubMed Web of Science ®Google Scholar
• CAESAR Coordinating Committee. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997;349:1413-21
   PubMed Web of Science ®Google Scholar
• Saag M, Knowles M, Chang Y, Durable effect of VIRACEPT (nelfinavir mesylate, NFV) in triple combination therapy [abstract I-101]. In: Program and Abstracts of the 37th Interscience Conference of Antimicrobial Agents and Chemotherapy; American Society of Microbiology; 28 September – 1 October 1997; Toronto. American Society of Microbiology, Washington, DC; 1997. p. 261-2
   Google Scholar
• Hammer SM, Squires KE, Hughes MD, A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-33
   PubMed Web of Science ®Google Scholar
• Gulick RM, Mellors JW, Havlir D, Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9
   PubMed Web of Science ®Google Scholar
• Eron J, Yetzer E, Poertz D, Combivir, a fixed dose formulation of lamivudine (3TC) 150 mg and zidovudine (ZDV) 300 mg, given BID plus a protease inhibitor (PI) compared to 3TC 150 mg BID and ZDV 200 mg TID plus a PI [abstract no. 387c]. In: Programs and Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; Infectious Diseases Society of America; 1 – 5 February 1998; Chicago. Foundation for Retrovirology and Human Health, Alexandria, VA; 1998. p. 151
   Google Scholar
• Rozenbaum W, Chauveau E. Phase 3 study of the antiviral activity of AZT and 3TC given as separate regimens versus a new fixed dose combination (Combivir) [abstract no 669]. In: Programs and Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; Infectious Diseases Society of America; 1 – 5 February 1998; Chicago. Foundation for Retrovirology and Human Health, Alexandria, VA; 1998. p. 205
   Google Scholar
• Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996;348:283-91
   PubMed Web of Science ®Google Scholar
• Hammer SM, Katzenstein DA, Hughes MD, A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996;335:1081-90
   PubMed Web of Science ®Google Scholar
• Arribas JR, Pozniak AL, Gallant JE, Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr 2008;47:74-8
   PubMed Web of Science ®Google Scholar
• Gulick RM, Ribaudo HJ, Shikuma CM, Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA 2006;296:769-81
   PubMed Web of Science ®Google Scholar
• Kumar PN, Rodriguez-French A, Thompson MA, ; for the ESS40002 Study Team. A prospective, 96-week study of the impact of trizivir, combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity. HIV Med 2006;2:85-98
   Web of Science ®Google Scholar
• Kumar PN, Salvato P, Lamarca A, A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study). AIDS Res Ther 2009;6:3
   PubMedGoogle Scholar
• Dumond JB, Yeh RF, Gathe J Jr, for the KLEAN Study Team. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet 2006;368:476-82
   PubMed Web of Science ®Google Scholar
• Smith KY, Patel P, Fine D, for the HEAT Study Team. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS 2009;23:1547-56
   PubMed Web of Science ®Google Scholar
• Hogg RS, Yip B, Kully C, Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. CMAJ 1999;160:659-65
   PubMed Web of Science ®Google Scholar
• Lai CL, Chien RN, Leung NW, A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61-8
   PubMed Web of Science ®Google Scholar
• Dienstag JL, Schiff ER, Wright TL, Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-63
   PubMed Web of Science ®Google Scholar
• Dienstag JL, Goldin RD, Heathcote EJ, Histological outcome during long-term lamivudine therapy. Gastroenterology 2003;124:105-17
   PubMed Web of Science ®Google Scholar
• Al Faraidy K, Yoshida EM, Davis JE, Alteration of the dismal natural history of fibrosing choleostatic hepatitis secondary to hepatitis B virus with the use of lamivudine. Transplantation 1997;64:926-8
   PubMed Web of Science ®Google Scholar
• Deinstag JL, Perrillo RP, Schiff ER, A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-61
   PubMed Web of Science ®Google Scholar
• Lai C-L, Ching C-K, Tung AK-M, Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology 1997;25:241-4
   PubMed Web of Science ®Google Scholar
• Nevens F, Main J, Hoonkoop P, Lamivudine therapy for chronic hepatitis B – a six-month randomized dose-ranging study. Gastroenterology 1997;113:1258-63
   PubMed Web of Science ®Google Scholar
• Vanthiel DH, Friedlander L, Kania RJ, Lamivudine treatment of advanced and decompensated liver disease due to hepatitis B. Hepatogastroenterology 1997;44:808-12
   PubMed Web of Science ®Google Scholar
• Scott Letendre, E Capparelli, B Best, for the CHARTER Group. Better antiretroviral penetration into the central nervous system is associated with lower CSF viral load. 13th CROI 2006; Denver, Feb 5-8, 2006. Abstract 74
   Google Scholar
• Dumond JB, Yeh RF, Patterson KB, Antiretroviral drug exposure in the female genital tract : implications for oral pre-and post-exposure prophylaxis. AIDS 2007;21:1899-907
   PubMed Web of Science ®Google Scholar
• Dumond JB, Reddy YS, Troiani L, Differential extracellular and intracellular concentrations of zidovudine and lamivudine in semen and plasma of HIV-1-infected men. J Acquir Immune Defic Syndr 2008;48:156-62
   PubMed Web of Science ®Google Scholar
• Yuen GJ, Lou Y, Bumgarner NF, Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily. Antimicrob Agents Chemother 2004;48:176-82
   PubMed Web of Science ®Google Scholar
• Lewis LL, Venzon D, Church J, Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group. Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group. J Infect Dis 1996;174:16-25
   PubMed Web of Science ®Google Scholar
• van Leeuwen R, Lange JM, Hussey EK, The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study. The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study. AIDS 1992;6:1471-5
   PubMed Web of Science ®Google Scholar
• Moodley J, Moodley D, Pillay K, Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J Infect Dis 1998;178:1327-33
   PubMed Web of Science ®Google Scholar
• Johnson MA, Verpooten GA, Daniel MJ, Single dose pharmacokinetics of lamivudine in subjects with impaired renal function and the effect of haemodialysis. Br J Clin Pharmacol 1998;46:21-7
   PubMed Web of Science ®Google Scholar
• Eron JJ Jr. The treatment of antiretroviral-naive subjects with the 3TC/zidovudine combination: a review of North American (NUCA 3001) and European (NUCB 3001) trials. AIDS 1996;(10 Suppl 5):S11-19
   Google Scholar
• DeJesus E, McCarty D, Farthing CF, ; for the EPV20001 International Study Team. Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial. Clin Infect Dis 2004;39:411-18
   PubMed Web of Science ®Google Scholar
• Gulick RM, Ribaudo HJ, Shikuma CM, ; AIDS Clinical Trials Group Study A5095 Team. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. NEJM 2004;350:1850-61
   PubMed Web of Science ®Google Scholar
• Staszewski S, Keiser P, Montaner J, Abacavir-lamivudine-zidovudine vs indinavir- lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: a randomized equivalence trial. JAMA 2001;285:1155-63 [Erratum, JAMA 2001;285:2858]
   PubMed Web of Science ®Google Scholar
• Vibhagool A, Cahn P, Schechter M, Abacavir/combivir (ABC/COM) is comparable to indinavir/combivir in HIV-1 infected antiretroviral therapy naïve adults: preliminary results of a 48-week open label study (CNA3014) [abstract 20]. In: Final Programme and Abstracts of the 1st IAS Conference on HIV Pathogenesis and Treatment; 8 – 11 July 2001; Buenos Aires, Argentina; p. 102
   Google Scholar
• Matheron S, Descamps D, Boue F, Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial. Antivir Ther 2003;8:163-71
   PubMed Web of Science ®Google Scholar
• Gallant JE, Rodriguez AE, Weinberg WG, Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis 2005;192:1921-30
   PubMed Web of Science ®Google Scholar
• Khanlou H, Yeh V, Guyer B, Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients. AIDS Patient Care STDS 2005;19:135-40
   PubMed Web of Science ®Google Scholar
• Delaunay C, Brun-Vezinet F, Landman R, Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021). J Virol 2005;79:9572-8
   PubMed Web of Science ®Google Scholar
• Jemsek G, Hutcherson P, Harper E. Poor virologic responses and early emergence of resistance in treatment naive, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir DF [abstract 51]. 11th Conference on Retroviruses and Opportunistic Infections; San Francisco, USA; 2004
   Google Scholar
• Moyle GJ, DeJesus E, Cahn P, ; for the Ziagen Once-Daily in Antiretroviral Combination Therapy (CNA30021) Study Team. Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the ziagen once daily in antiretroviral combination study. J AIDS 2005;38:417-25
   PubMed Web of Science ®Google Scholar
• DeJesus E, Herrera G, Teofilo E, ; for the CNA30024 Study Team. Abacavir versus zidovudine combined with lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults. CID 2004;39:1038-46
   PubMed Web of Science ®Google Scholar
• Pulido F, Estrada V, Baril JG, Long-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 weeks. HIV Clin Trials 2009;10:76-87
   PubMed Web of Science ®Google Scholar
• Lamarca A, Clumeck N, Plettenberg A, Efficacy and safety of a once-daily fixed-dose combination of abacavir/lamivudine compared with abacavir twice daily and lamivudine once daily as separate entities in antiretroviral-experienced HIV-1-infected patients (CAL30001 Study). J AIDS 2006;41:598-606
   PubMed Web of Science ®Google Scholar
• McKinney RE Jr, Johnson GM, Stanley K, A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team. J Pediatr 1998;133:500-8
   PubMed Web of Science ®Google Scholar
• Paediatric European Network for Treatment of AIDS (PENTA). Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial. Lancet 2002;359:733-40
   PubMed Web of Science ®Google Scholar
• Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002;46:716-23
   PubMed Web of Science ®Google Scholar